Department of Surgery

Weill Cornell Medical College of Cornell University, USA

Professor

Email: aogaber@tmhs.org

Qualifications

1976 MBBCh, Ainshams University School of Medicine

Publications (selected)

1. Cheadle C, Watkins T, Ehrilich E, Barnes K, A.O Gaber A, Hemmerich S, Rabb H: Effects of anti-adhesive therapy on kidney biomarkers of ischemia reperfusion injury in human deceased donor kidney allografts (1,2). Clin. Transplant, 2011 Nov 28: 1399-0012.
2. Soltero L, Carbajal H, Xu J, McCarthy J, Suki WN, Gaber AO, Adrogué HE.Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy. Clin Transplant. 2012 Mar-Apr; 26(2): 300-4.
3. Gaber AO, Mulgaonkar S., Kahan B.D., Steve Woodle E., Alloway R, Bajjoka I, Jensik S.,Klintmalm G.B., Patton P.R., Wiseman A., Lipshutz G., Kupiec-Weglinski J., Gaber L.W., Katz E.,Irish W, Squiers E.C., Hemmerich S. YSPSL (rPSGL-Ig) for improvement of early renal allograft Function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant. 2010; June 22.
4. Gaber AO, Monaco, A.P., Russell, J.A., Lebranchu, Y., Mohty, Mohammad. Rabbit AntithymocyteGlobulin (Thymoglobulin®): 25 Years and New Frontiers in Solid Organ Transplantation and Haematology. Drugs 2010; 70(6): 691-732.
5. Knight, RJ, Lawless A, Patel SJ, Gaber AO. Simultaneous kidney-pancreas transplantation for end-stage renal disease patients with insulin-dependent diabetes and detectable C-peptide. Transplant Proc. 2010 Dec; 42(10): 4195-6.
6. Gainer SM, Patel SJ, Seethamraju H, Moore LW, Knight RJ, Gaber, AO: Increased mortality of solid organ transplant recipient with H1N1 infrection: A singe center experience. Clin. Transplant, 2011 April.
7. Labib HA, Etwa RL, Gaber OA, Atfy M, Mostafa TM, Barsoun I. Paraoxonase-1 and oxidative status in common Mediterranean B-thalassaemia mutations trait, and their relations to atherosclerosis. J. Pathology. 2011, May; 64(5): 437-42.
8. Dawson KL, Patel SJ, Xui J, Knigth RJ, Gaber AO. Effect of immunosuppression for first kidney or kidney/pancreas transplant on sensistization at the time of second transplant. Transplantation. 2011, April 15; 91(7): 751-6.
9. Patel SJ, Knight SJ, Suki WN, Abdellatif A, Durhart BT Jr, Krauss AG, Mannam S, Nezakatgoo N, A.O Gaber Rabbit antithymoycte induction and dosing in deceased donor renal transplant recipients over 60 yrs if age. Clin. Transplant, 2011 May; 25(3): E250-6.
10. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant, 2011 Dec; 11(12): 2675-84.
11. DeVos JM, Patel SJ, Xu J, Knight RJ, Gaber AO, Land GA. De novo donor specific antibodies and patient outcomes in renal transplantation. Clin Transpl. 2011: 351-8.
12. Soltero L, Carbajal H, Xu J, McCarthy J, Suki WN, Gaber AO, Adrogue HE. Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy. ClinTransplant, 2012 Mar-Apr; 26(2): 300-4.
13. Gaber A Osama, Matas Arthur J, Henry Mitchell L, Brennan Daniel C, Stevens R Brian, Kapur Sandip, Ilsley Jillian N, Kistler Kristen D, Cosimi A Benedict. Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients: Final Report of the TAILOR registry. Transplantation, 2012 Aug 27; 94(4): 331-7.
14. DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, Patel, SJ. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int. 2012 Sep; 821(5): 598-604.
15. Gaber AO, Moore LW, Aloia TA, Suki WN, Jones SL, Graviss EA, Knight RJ, Bass BL. Cross-sectional and Case-control Analyses of the Association of Kidney Function Staging with Adverse Postoperative Outcomes in General and Vascular Surgery. Ann Surg 2012 (in press).
16. Moore, LW, Byham-Gray L, Parrott JS, Rigassio-Radler D, Mandayam S, Jones SL, Mitch WE, Gaber AO. Dietary Protein Intake of Adults across the Stages of Chronic Kidney Disease from the National Health and Nutrition Examination Survey, 2001-2008. Kidney Int advance online publication, January 9, 2013.
17. Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch J, Shihab F, Henning A, Fitzsimmons W, Holman J, Reisfield R. Characteristics of acute rejection in a prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Transplantation (in press) Feb 2013.
18. Shihab FS, Lee ST, Smith LD, Woodle ES, Pirsch JD, Gaber AO, Henning AK, Reisfield R, Fitsimmons W, Holman J. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in randomized multicenter study. AMJ Transplant, 2013 Feb; 13(2): 474-84.
19. Stamatakis L, Mercado MA, Choi JM, Sanchez EJ, Gaber AO, Knight RJ, Mayer WA, Link RE. Comparison of laparoendoscopic single site (LESS) and conventional laparoscopic donor nephrectomy at a single institution. BJU Int. 2013 Mar 11.
20. Knight RJ, Gaber LW, Patel SJ, Devos JM, Moore LW, Gaber AO. Screening for BK Viremia Reduces but Does Not Eliminate the Risk of BK Nephropathy: A Single-Center Retrospective Analysis. Transplantation, 2013 Apr 15; 95(7): 949-54.
21. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients. Transplantation. 2013 Jul 27; 96(2): 191-7.
22. Gaber AO, Shokouh-Amiri, MH. Simultaneous Pancreas Kidney: Portal/Enteric Drainage. In: Atlas of Organ Transplantation edited by Abhinav Humar, William D. Payne and Arthur J. Matas, Springer-Verlag, London, 2006. pp. 154-178.